# OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD

> **NCT07450820** · — · RECRUITING · sponsor: **AstraZeneca** · enrollment: 14308 (estimated)

## Conditions studied

- Chronic Kidney Disease

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT07450820
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-18
- **Primary completion:** 2027-02-09
- **Final completion:** 2027-02-09
- **Target enrollment:** 14308 (ESTIMATED)
- **Last updated:** 2026-04-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07450820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07450820, "OPTIMISE-CKD Study_Dapagliflozin Effectiveness in CKD". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07450820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*